<DOC>
	<DOCNO>NCT02094625</DOCNO>
	<brief_summary>Cisplatin key chemotherapy agent treatment multiple childhood cancer cause permanent hearing loss . This study investigate drug N-acetylcysteine ( NAC ) determine dose necessary protect hearing also well tolerate NAC combine chemotherapy .</brief_summary>
	<brief_title>NAC Prevent Cisplatin-induced Hearing Loss</brief_title>
	<detailed_description>The study dose-finding study N-acetylcysteine ( NAC ) protect hear child receive cisplatin treatment cancer . NAC also potential protect kidney cisplatin toxicity . The study use 3+3 dose-escalation scheme determine dose NAC necessary achieve serum level consistent hear protection pre-clinical animal model . Three dose level predefined . Once maximum tolerate dose determine , expansion cohort enrol evaluate tolerability well intra-patient inter-patient variability achieve serum level . An option enroll separate arm study assessment available wish receive NAC . Hearing loss cohort assess entire cohort comparison historical non-treated child evaluate trend toward efficacy .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hearing Loss</mesh_term>
	<mesh_term>Deafness</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Are 1 21 year age ( inclusive ) time diagnosis underlie malignancy Have new diagnosis localize malignancy plan treatment course include least two cycle cisplatin Diagnosis assign oncology attend record ( may report via designee ) , histological diagnosis need confirm separately Most common exclusive diagnosis consist highrisk neuroblastoma , hepatoblastoma , germ cell tumor , medulloblastoma , osteosarcoma Total cumulative dose plan cisplatin must &gt; 200 mg/m2 ( 6.67 mg/kg equivalent infant require weightbased dose . Conversion factor use 30:1 ) . Planned cisplatin dose infuse â‰¤6 hour Are anticipate able comply endoftherapy audiology assessment ( note hearing assessment perform per routine clinical care child receive cisplatin consist audiogram auditory brainstem response , distortionproduct otoacoustic emission ) Patients hear status eligible study ( long comply study primary aim assess toxicity doseresponse ) preexisting risk serious arrhythmia define ( ) normal sinus rhythm electrocardiogram correct QT interval &lt; 500 ( b ) previous history congenital arrhythmia ( e.g . WolfParkinsonWhite ) Hepatic , biliary , cardiac , bone marrow function inadequate chemotherapy per patient 's treatment regimen . There additional protocolspecific restriction marker . Moderate Severe Persistent Asthma define late recommendation National Heart Lung Blood Institute definition include daily asthma exacerbation need rescue medication ) overnight hospitalization asthma exacerbation within previous 28 day Disseminated disease ( e.g . leptomeningeal spread , tumor metastasis ) Karnofsky Lansky score &lt; 50 % Pregnancy breastfeeding mother Documented hypersensitivity allergy previous NAC infusion</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Cisplatin</keyword>
	<keyword>N-acetylcysteine</keyword>
	<keyword>Hearing Loss</keyword>
	<keyword>Otoprotection</keyword>
</DOC>